PPD, commonly referred to as postnatal depression, is a type of mood illness that occurs after a pregnancy. Insomnia, exhaustion, and melancholy are all symptoms of depression, as are loss of appetite, mood swings, worry, and hostility. Hormonal abnormalities in females, such as high prolactin, reduced oxytocin, and thyroid hormone levels, might induce PPD.
The global postpartum depression medicine market is divided
into North America, Latin America, Europe, Asia Pacific, the Middle East, and
Africa based on region.
Due to rising awareness of PPD, North America is expected to
dominate the worldwide postpartum
depression drug market over the forecast period. For example,
May 2017 is designated as National Maternal Depression Awareness Month in the
United States, emphasizing the significance of depression during and after
pregnancy.
Furthermore, due to the rising frequency of PDD in the Asia
Pacific, the worldwide postpartum depression drug market is predicted to rise
significantly during the forecast period. According to a World Health
Organization (WHO) research from July 2018, 22 percent of Indian women suffer from
PPD on an annual basis.
The postpartum depression drug market is predicted to develop
at a faster rate than the overall market during the forecast period, thanks to
increased research activity for the treatment of PPD. Sage Therapeutics, for
example, is currently conducting a phase 3 clinical trial for the medication
Brexanolone, which may be effective in the treatment of PPD. The research began
in May 2018 and is expected to be finished in September 2020.